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morbidity and mortality is highly desirable. Elevated albu-
minuria levels have proven to predict worse cardiovascular
outcomes. The aim of our study was to estimate the cost-
effectiveness and of a population-based ‘screen-and-treat’ proce-
dures directed at albuminuria. METHODS: A formal cost-
effectiveness analysis was conducted using a Markov-model
for disease progression. The model consist of 8 health states
deﬁned by urinary albumine excretion (UAE) classiﬁcation
(UAE < 15 mg/day (low-normo), UAE 15–30 mg/day (high-
normo), UAE 30–300 mg/day (micro), 300 mg/day (macro)),
cardiovascular morbidity, cardiovascular mortality, non-
cardiovascular mortality and renal disease (e.g. dialysis). Input-
variables for transitions between albuminuria-based Markov
stages and effects of blood pressure lowering agents were
derived from the observational PREVEND cohort study and
PREVEND-IT clinical trial. All costs were presented in 2008
values and the cost-effectiveness analysis was performed follow-
ing the Dutch guidelines for conducting pharmacoeconomic
research. RESULTS: Early results for screening the Dutch popu-
lation on albuminuria (15 mg/day) and subsequent ACE-
inhibitor treatment in those found positive, suggests a crude
cost-effectiveness of €29,300 per life year gained (LYG). Treating
only those subjects with microalbuminuria (30 mg/day)
resulted to be more favorable with a cost-effectiveness of €9700
per LYG. Furthermore, restricting screening to only those
subjects aged >50 or >60 years resulted in a cost-effectiveness of
respectively €15,000 and €10,200 per LYG. These age-dependent
ﬁgures were even more favorable in those subjects with
microalbuminuria. Our preliminary results suggest a favorable
cost-effectiveness outcome below the (informal) Dutch pharma-
coeconomic threshold of €20,000 per LYG. CONCLUSIONS:
Next to the cost-effectiveness outcomes from the PREVEND-IT
economic evaluation, our results on observational data suggest
favorable cost-effectiveness outcomes for a population-based
‘screen-and-treat’ procedure on albuminuria. Deﬁnite results
including probabilistic sensitivity analyses will be presented
during the conference.
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OBJECTIVES: To compare the short-term cost-effectiveness of
simultaneously achieving multiple lipid targets when fenoﬁbric
acid (FA) is co-administered with simvastatin, rosuvastatin, and
atorvastatin. METHODS: A dyslipidemia outcomes model was
used to estimate multiple lipid goal attainment (any 3 of 4
targets: total-C, LDL-C, HDL-C, TG) and associated costs over
one year in a patient cohort with multiple lipid abnormalities.
Lipid goal threshold values were based on U.S. clinical practice
guidelines. Baseline lipid values and lipid efﬁcacy data were
obtained from three 12-week FA/statin studies, where FA 135 mg
co-administered with atorvastatin, rosuvastatin, and simvastatin
at low (20 mg, 10 mg, 20 mg, respectively) and moderate doses
(40 mg, 20 mg, 40 mg, respectively) was compared to FA and
equivalent doses of each statin monotherapy. Net drug costs were
estimated. Drug costs were based on wholesale acquisition costs
and were assumed additive. Patient copays were based on
national averages. RESULTS: The predicted rate per 1,000
patients achieving 3 lipid targets with the co-administration of
FA and low-dose simvastatin, rosuvastatin, and atorvastatin was
678, 814, and 723, respectively. Per member per month drug
costs for each low-dose combination were estimated at $24.09,
$39.63, and $41.40, respectively. The estimated per patient costs
per three lipid goals achieved were $1279, $1753, and $2062 for
each respective low-dose combination. The incremental cost
effectiveness ratio (ICER) for one additional patient achieving 3
lipid targets when FA is combined with low-dose rosuvastatin
and atorvastatin relative to simvastatin is $4,113 and $13,849,
respectively. For the moderate-dose combinations, qualitative
results are similar though ICERs versus simvastatin for rosuvas-
tatin and atorvastatin were 1.4–11.2 times higher, respectively.
CONCLUSIONS: Adding FA 135 mg to simvastatin 20 mg and
40 mg yields the lowest annualized cost per patient achieving 3
lipid targets compared to equivalent dose combinations of FA
with rosuvastatin and atorvastatin.
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OBJECTIVES: An ICM is a programmable monitoring system
that stores a patient’s subcutaneous ECG and other diagnostic
information. Its features are aimed at detecting arrhythmias and
their long term trending. Since long-term continuous AF moni-
toring is not yet used in patients with PAAF in Spain, its impli-
cations in the management of these patients (including possible
OAC discontinuation) are still unknown. This study aimed to
model the cost-effectiveness of OAC management using ICMs in
patients treated with radiofrequency catheter ablation for atrial
ﬁbrillation (PAAF) in Spain. METHODS: A Markov model was
built to simulate the outcomes and costs of Standard of Care
(SOC, traditional intermittent 24H monitors) and continuous
AF monitoring with an ICM (Reveal XT). Efﬁcacy data was
obtained from clinical studies showing that Reveal was able to
detect asymptomatic episodes in AF patients, thus facilitating an
optimized disease management that may reduce long-term com-
plications incidence. The risks of stroke, adverse events manage-
ment and utility ﬁgures where taken from international
literature; local Spanish costs where used to model the economic
consequences of PAAF for three years. Costs and effects were
discounted at 3%. RESULTS: Model results show that the con-
tinuous long-term AF monitoring with ICMs may be associated
to a gain of 0.16 at an extra cost of €6100, showing an iCER of
€37,994 per QALY gained. Sensitivity analysis showed an impor-
tant uncertainty regarding the effectiveness of ICMs, with a 95%
CI of QALY gains of 0.11–0.21. CONCLUSIONS: The prelimi-
nary results of this study show that ICMs may improve PAAF
outcomes but extra health care costs are to be considered. Longer
follow-up analyses and inclusion of eventual quality of life gains
associated to the reduction of uncertainty of patients regarding
their disease, may improve the economic value of this novel
strategy using AF monitoring systems.
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OBJECTIVES: In the Eplerenone Post-Acute Myocardial Infarc-
tion Heart Failure Efﬁcacy and Survival Study (EPHESUS),
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